TABLE 5.
Drug-related adverse events after single oral dose of contezolid, moxifloxacin, or placebo in healthy Chinese subjects
| Variable | No. (%) of subjects with TEAEs |
||||
|---|---|---|---|---|---|
| Placebo (n = 52) | Moxifloxacin (n = 52) | Contezolid, 800 mg (n = 52) | Contezolid, 1,600 mg (n = 52) | Sum (n = 52) | |
| Drug-related adverse event | 3 (5.8) | 7 (13.5) | 5 (9.6) | 14 (26.9) | 21 (40.4) |
| Gastrointestinal disorders | 2 (3.8) | 3 (5.8) | 3 (5.8) | 10 (19.2) | 15 (28.8) |
| Nausea | 1 (1.9) | 1 (1.9) | 2 (3.8) | 10 (19.2) | 11 (21.2) |
| Vomiting | 0 | 0 | 1 (1.9) | 5 (9.6) | 5 (9.6) |
| Diarrhea | 1 (1.9) | 0 | 1 (1.9) | 0 | 2 (3.8) |
| Abdominal bloating | 0 | 2 (3.8) | 0 | 0 | 2 (3.8) |
| Upper abdominal discomfort | 0 | 0 | 1 (1.9) | 0 | 1 (1.9) |
| Laboratory test | 1 (1.9) | 4 (7.7) | 2 (3.8) | 3 (5.8) | 6 (11.5) |
| Serum uric acid elevation | 0 | 2 (3.8) | 2 (3.8) | 1 (1.9) | 3 (5.8) |
| White blood cell count decrease | 0 | 1 (1.9) | 0 | 0 | 1 (1.9) |
| Alanine aminotransferase elevation | 1 (1.9) | 0 | 0 | 0 | 1 (1.9) |
| Direct bilirubin elevation | 0 | 0 | 0 | 1 (1.9) | 1 (1.9) |
| Aspartate aminotransferase elevation | 1 (1.9) | 0 | 0 | 0 | 1 (1.9) |
| Bilirubin elevation | 1 (1.9) | 0 | 0 | 0 | 1 (1.9) |
| Hemoglobin decrease | 0 | 1 (1.9) | 0 | 1 (1.9) | 1 (1.9) |
| Neutrophil percent decrease | 0 | 1 (1.9) | 0 | 0 | 1 (1.9) |
| Neutrophil count decrease | 0 | 1 (1.9) | 0 | 0 | 1 (1.9) |
| Neurological disorders | 0 | 0 | 0 | 2 (3.8) | 2 (3.8) |
| Headache | 0 | 0 | 0 | 1 (1.9) | 1 (1.9) |
| Dizziness | 0 | 0 | 0 | 1 (1.9) | 1 (1.9) |